Closed-loop adaptive adjustment of pacing therapy based on cardiogenic impedance signals detected by an implantable medical device

• US 8,712,519 B1
• Filed: 11/09/2006
• Issued: 04/29/2014
• Est. Priority Date: 03/31/2006
• Status: Active Grant

• Current Assignee: Pacesetter Incorporated (Abbott Laboratories)
• Original Assignee: Pacesetter Incorporated (Abbott Laboratories)
• Inventors: Panescu, Dorin, Yang, Weiqun, Wong, Louis, Holmstrom, Nils, Walker, Andre
• Primary Examiner(s): Porter, Jr., Allen
• Application Number:
  US11/558,194
• Time in Patent Office: 2,728 Days
• Field of Search: 607/2, 607/6, 607/7, 607/11, 607/17, 607/18, 607/20, 607/23, 607/28, 607/9, 600/547
• US Class Current: 607/9
• CPC Class Codes: A61N 1/3627 for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy
• CPC Class Codes: A61N 1/36521 the parameter being derived from measurement of an electrical impedance
• CPC Class Codes: A61N 1/3684 for stimulating the heart at multiple sites of the ventricle or the atrium
• CPC Class Codes: A61N 1/36842 Multi-site stimulation in the same chamber
• CPC Class Codes: A61N 1/36843 Bi-ventricular stimulation

Abstract

Techniques are provided for controlling therapy provided by the implantable cardiac stimulation device based on cardiogenic impedance. A cardiogenic impedance signal (or intracardiac impedance signal) is an impedance signal representative of the beating of the heart of the patient in which the device is implanted. The cardiogenic impedance signal is sensed along a sensing vector passing through at least a portion of the heart so that the sensed impedance is affected by the mechanical beating of the heart along that sensing vector. Pacing therapy is automatically and adaptively adjusted based on the cardiogenic impedance signal. For example, pacing timing parameters such as the atrioventricular delay and the inter-ventricular delay may be adjusted. Preferably, the adjustments are adaptive, i.e. the adjustments are performed in a closed-loop so as to adapt the adjustments to changes in the cardiogenic impedance signal so as to optimize therapy. In one particular example, the adjustments are performed so as to reduce a degree of fractionation within a cardiogenic impedance waveform.

Claims

1. A method for controlling therapy provided by an implantable cardiac stimulation device to reduce mechanical dyssynchrony, the method comprising:

detecting an interventricular cardiogenic impedance signal (Z_C) associated with individual heartbeats with the interventricular cardiogenic impedance signal having an interventricular waveform morphology, the interventricular cardiogenic impedance signal having sufficient resolution to detect a notch within an individual heartbeat occurring even in the absence of mechanical dyssynchrony, the interventricular waveform morphology of individual heartbeats having additional features corresponding to periods of time when chambers of the heart are not beating uniformly due to mechanical dyssynchrony;

deriving a measure of interventricular fractionation from the interventricular waveform morphology, wherein interventricular fractionation quantifies the features of the interventricular waveform morphology of individual heartbeats corresponding to periods of time when chambers of the heart are not beating uniformly due to mechanical dyssynchrony; and

adjusting therapy provided by the device based on the interventricular cardiogenic impedance signal (Z_C) to improve the measure of interventricular fractionation and reduce periods of time when chambers of the heart are not beating uniformly due to mechanical dyssynchrony;

wherein the features of the interventricular waveform morphology corresponding to periods of time when chambers of the heart are not beating uniformly due to mechanical dyssynchrony include a plurality of additional notches within an individual heartbeat arising due to mechanical dyssynchrony and wherein therapy is adjusted to reduce at least one of the plurality of additional notches within the individual heartbeat to reduce interventricular fractionation and reduce mechanical dyssynchrony.

2. The method of claim 1 wherein detecting an interventricular cardiogenic impedance signal (Z_C) includes:

measuring a raw impedance signal (Z₀) along at least one sensing vector passing through at least a portion of both ventricles of the heart of a patient in which the device is implanted; and

extracting the interventricular cardiogenic impedance signal (Z_C) from the raw impedance signal (Z₀), wherein the cardiogenic impedance signal (Z_C) is representative of variations in impedance due to the beating of the heart of the patient including the beating of both ventricles.

3. The method of claim 2 wherein extracting the cardiogenic impedance signal (Z_C) from the raw impedance signal (Z₀) includes extracting a signal representative of a change in Z_C with respect to time (dZ_C/dt) and wherein the measure of interventricular fractionation is derived from the signal representative of a change in Z_C with respect to time.

4. The method of claim 2 wherein extracting the cardiogenic impedance signal (Z_C) from the raw impedance signal (Z₀) includes extracting a signal representative of a difference between maximum and minimum cardiogenic impedance values (Z_C-max-Z_C-max) and wherein the measure of interventricular fractionation is derived from the signal representative of a difference between maximum and minimum cardiogenic impedance values.

5. The method of claim 1 further including storing the cardiogenic impedance signal (Z_C) using signal compression.

6. The method of claim 5 wherein signal compression is achieved by selectively storing cardiogenic impedance values within histogram bins.

7. The method of claim 1 wherein separate interventricular cardiogenic impedance signals are detected along separate sensing vectors passing through at least a portion of both ventricles of the heart of the patient and wherein separate measures of interventricular fractionation are derived from the separate interventricular cardiogenic impedance signals and wherein therapy is adjusted based on a combination of the separate measures of interventricular fractionation.

8. The method of claim 7 wherein multiple impedance sensing electrodes are provided along at least one ventricular lead and wherein the separate cardiogenic impedance signals are derived using the multiple electrodes of the at least one ventricular lead in combination with at least one electrode of at least one other lead.

9. The method of claim 7 wherein multiple impedance sensing electrodes are provided along a plurality of ventricular leads and wherein the separate cardiogenic impedance signals are derived using the electrodes of the plurality of ventricular leads.

10. The method of claim 1 further including identifying trends in changes in interventricular fractionation.

11. The method of claim 10 wherein deriving a value representative of cardiac pressure includes deriving a value representative of one or more of left atrial pressure (LAP) and left ventricular end diastolic pressure (LV_END).

12. The method of claim 1 further including deriving a value representative of cardiac pressure from the cardiogenic impedance signal (Z_C) and wherein therapy is adjusted to improve both the value representative of cardiac pressure derived from the cardiogenic impedance signal (Z_C) and the measure of interventricular fractionation.

13. The method of claim 1 further including detecting an intracardiac electrogram (IEGM) signal and deriving a measure of electrical dyssynchrony from the intracardiac electrogram (IEGM) signal and wherein therapy is adjusted to improve both the measure of electrical dyssynchrony and the measure of interventricular fractionation.

14. The method of claim 1 further including detecting a significant deterioration in the measure of interventricular fractionation.

15. The method of claim 14 further including activating a warning device in response to detection of a significant deterioration in the measure of interventricular fractionation.

16. The method of claim 1 further including deriving a value representative of cardiac pressure from a cardiac pressure sensor and wherein therapy is adjusted to improve both the measure of cardiac pressure derived from the cardiac pressure sensor and the measure of interventricular fractionation.

17. The method of claim 1 wherein adjusting therapy provided by the device is performed in a closed loop based on repeatedly updated measures of interventricular fractionation.

18. The method of claim 1 wherein therapy is adjusted by adjusting one or more pacing timing parameters.

19. The method of claim 18 wherein therapy is adjusted by adjusting an atrioventricular (AV) timing parameter.

20. The method of claim 18 wherein therapy is adjusted by adjusting an inter-ventricular (LV-RV) timing parameter.

21. The method of claim 18 wherein therapy is adjusted by adjusting an intra-ventricular (LV₁-LV₂, RV₁-RV₂) timing parameter.

22. The method of claim 18 wherein pacing timing parameters are adjusted to reduce one or more of:

inter-ventricular mechanical dyssynchrony (LV-RV);

intra-ventricular mechanical dyssynchrony (LV₁-LV₁, LV₁-LV₁);

inter-ventricular electrical dyssynchrony (LV-RV);

intra-ventricular electrical dyssynchrony (LV₁-LV₁, LV₁-LV₁);

inter-atrial mechanical dyssynchrony (LV-RV);

intra-atrial mechanical dyssynchrony (LV₁-LV₁, LV₁-LV₁);

inter-atrial electrical dyssynchrony (LV-RV);

intra-atrial electrical dyssynchrony (LV₁-LV₁, LV₁-LV₁); and

a fractionation index.

23. The method of claim 18 wherein pacing timing parameters are adjusted to improve one or more of left atrial pressure (LAP), LV_END pressure, stroke volume, cardiac output, SO₂, and cardiac contractility.

24. The method of claim 1 wherein therapy is adjusted based on cardiogenic impedance signals detected only during particular patient activity levels as determined in conjunction with an activity sensor.

25. The method of claim 1 wherein therapy is adjusted based on cardiogenic impedance signals detected only while the patient is in a particular posture as determined in conjunction with a position sensor.

26. The method of claim 1 wherein therapy is adjusted based on cardiogenic impedance signals detected only while the patient has a particular blood oxygen saturation level as determined in conjunction with a blood oxygen saturation sensor.

27. The method of claim 1 wherein therapy is adjusted substantially in real-time.

28. The method of claim 1 wherein the device is equipped to selectively deliver pacing at any of a plurality of pacing sites and wherein the step of adjusting therapy based on the interventricular cardiogenic impedance signal (Z_C) is performed to select particular ventricular pacing sites based on the cardiogenic impedance signal (Z_C) to improve cardiac performance by reducing interventricular fractionation.

29. The method of claim 1 wherein the device is equipped to selectively deliver pacing at any of a plurality of pacing sites and wherein the ventricular pacing sites are selected so as to improve the measure of interventricular fractionation.

30. The method of claim 29 wherein ventricular pacing sites are selected so as to additionally improve one or more of:

cardiac pressure, electrical dyssynchrony, cardiac performance, blood oxygen saturation, contractility, peak to peak amplitudes, and changes in cardiogenic impedance with time (dZ/dt).

31. The method of claim 1 wherein adjusting therapy includes:

detecting patient activity level, patient posture, blood oxygen saturation values (SO₂) and heart rate;

determining whether the patient is at rest and has been at rest for some predetermined amount of time, the posture is supine, SO₂ is within an acceptable predetermined range, and heart rate is within an acceptable predetermined range; and

if so, detecting at least one cardiogenic impedance signal Z_C along a vector emphasizing interventricular fractionation due to mechanical dyssynchrony within the supine posture, calculating the number of notches from a selected cardiogenic impedance signal Z_C, and adjusting timing parameters to reduce the number of notches.

32. The method of claim 1 wherein adjusting therapy includes adjusting a therapeutic stimulation control parameter in a given direction and then detecting and evaluating whether a time rate of change in the interventricular cardiogenic impedance signal (dZ_C/dt) exhibits a reversal in deterioration and, if so, performing further adjustments in the same direction and, if not, reversing the adjustment direction to reduce periods of time when chambers of the heart are not beating uniformly due to mechanical dyssynchrony.

33. The method of claim 1 wherein detecting an interventricular cardiogenic impedance signal (Z_C) includes:

acquiring an activity signal along with Z_C;

detecting dZ_C/dt and compiling trends in dZ_C/dt; and

evaluating whether the activity signal is within an acceptable range and, if so, determining whether dZ_C/dt indicates a deterioration of interventricular fractionation; and

wherein the step of adjusting therapy provided by the device is performed in response to an indication of deterioration of interventricular fractionation.

34. The method of claim 1 wherein the features of the interventricular waveform morphology corresponding to periods of time when chambers of the heart are not beating uniformly include higher spectral frequencies compared to spectral frequencies associated with periods of time when chambers of the heart are beating uniformly and wherein deriving a measure of interventricular fractionation includes deriving a measure of the higher spectral frequencies and wherein therapy is also adjusted to reduce the measure of the higher spectral frequencies to reduce interventricular fractionation.

35. The method of claim 1 wherein therapy is adjusted to reduce a number of notches within the individual heartbeat to reduce interventricular fractionation.

36. A system for controlling therapy provided by an implantable cardiac stimulation device to reduce the system comprising:

a cardiogenic impedance (Z_C) detector operative to detect an interventricular cardiogenic impedance signal (Z_C) associated with individual heartbeats, the interventricular cardiogenic impedance signal having an interventricular waveform morphology, the interventricular cardiogenic impedance signal having sufficient resolution to detect a notch within an individual heartbeat occurring even in the absence of mechanical dyssynchrony, the interventricular waveform morphology of individual heartbeats having additional features corresponding to periods of time when chambers of the heart are not beating uniformly due to mechanical dyssynchrony;

a cardiac function evaluation system operative to derive a measure of interventricular fractionation from the interventricular waveform morphology, wherein interventricular fractionation quantifies the features of the interventricular waveform morphology of individual heartbeats corresponding to the periods of time when chambers of the heart are not beating uniformly due to mechanical dyssynchrony; and

a cardiogenic impedance-based therapy adjustment system operative to adjust therapy provided by the device based on the interventricular cardiogenic impedance signal (Z_C) to improve the measure of interventricular fractionation and reduce periods of time when chambers of the heart are not beating uniformly due to mechanical dyssynchrony;

wherein the features of the interventricular waveform morphology corresponding to periods of time when chambers of the heart are not beating uniformly due to mechanical dyssynchrony include a plurality of additional notches within an individual heartbeat arising due to mechanical dyssynchrony and wherein the therapy adjustment system operates to adjust therapy to reduce at least one of the plurality of additional notches within the individual heartbeat to reduce interventricular fractionation and reduce mechanical dyssynchrony.

37. The system of claim 36 wherein the cardiogenic impedance-based therapy adjustment system includes a real-time adaptive cardiac resynchronization therapy (CRT) controller operative to adaptively adjust CRT parameters based on the cardiogenic impedance signal (Z_C) to improve the measure of interventricular fractionation.

38. The system of claim 36 wherein the device is equipped to selectively deliver pacing at any of a plurality of ventricular pacing sites and wherein the device further includes a pacing site selection system operative to select particular ventricular pacing sites based on the cardiogenic impedance signal (Z_C).

39. The system of claim 36 in an implantable cardiac stimulation device having at least one lead having a proximal end for connection to the implantable cardiac stimulation device and an opposing distal end, wherein the lead between its distal and proximal ends is helical with a decreasing radius of curvature from the proximal end to the distal end.

40. A system for controlling therapy provided by an implantable cardiac stimulation device to reduce mechanical dyssynchrony, the system comprising:

means for detecting an interventricular cardiogenic impedance signal (Z_C) associated with individual heartbeats, the interventricular cardiogenic impedance signal having an interventricular waveform morphology, the interventricular cardiogenic impedance signal having sufficient resolution to detect a notch within an individual heartbeat occurring even in the absence of mechanical dyssynchrony, the interventricular waveform morphology of individual heartbeats having additional features corresponding to periods of time when chambers of the heart are not beating uniformly due to mechanical dyssynchrony;

means for deriving a measure of interventricular fractionation from the interventricular waveform morphology, wherein interventricular fractionation quantifies the features of the interventricular waveform morphology of individual heartbeats corresponding to periods of time when chambers of the heart are not beating uniformly due to mechanical dyssynchrony; and

means for adjusting therapy provided by the device based on the interventricular cardiogenic impedance signal (Z_C) so as to improve the measure of interventricular fractionation and reduce periods of time when chambers of the heart are not beating uniformly due to mechanical dyssynchrony;

wherein the features of the interventricular waveform morphology corresponding to periods of time when chambers of the heart are not beating uniformly due to mechanical dyssynchrony include a plurality of additional notches within an individual heartbeat arising due to mechanical dyssynchrony and wherein the means for adjusting therapy operates to adjust therapy to reduce at least one of the plurality of additional notches within the individual heartbeat to reduce interventricular fractionation and reduce mechanical dyssynchrony.

41. A method for controlling therapy provided by an implantable cardiac stimulation device, the method comprising:

detecting an interventricular cardiogenic impedance signal (Z_C) associated with individual heartbeats with the interventricular cardiogenic impedance signal having an interventricular waveform morphology, the interventricular waveform morphology of individual heartbeats having features corresponding to periods of time when chambers of the heart are not beating uniformly due to mechanical dyssynchrony;

deriving a measure of interventricular fractionation from the interventricular waveform morphology, wherein interventricular fractionation quantifies the features of the interventricular waveform morphology of individual heartbeats corresponding to the periods of time when chambers of the heart are not beating uniformly due to mechanical dyssynchrony;

adjusting therapy provided by the device based on the interventricular cardiogenic impedance signal (Z_C) to improve the measure of interventricular fractionation and reduce periods of time when chambers of the heart are not beating uniformly due to mechanical dyssynchrony; and

wherein the features of the interventricular waveform morphology corresponding to periods of time when chambers of the heart are not beating uniformly due to mechanical dyssynchrony include higher spectral frequencies compared to spectral frequencies associated with periods of time when chambers of the heart are beating uniformly and wherein therapy is adjusted to reduce at least some of the higher spectral frequencies to reduce interventricular fractionation.

42. The method of claim 41 wherein separate interventricular cardiogenic impedance signals are detected along separate sensing vectors passing through at least a portion of both ventricles of the heart of the patient and wherein separate measures of interventricular fractionation are derived from the separate interventricular cardiogenic impedance signals and wherein therapy is adjusted based on a combination of the separate measures of interventricular fractionation.

43. The method of claim 41 further including identifying trends in changes in interventricular fractionation.

44. The method of claim 41 further including detecting an intracardiac electrogram (IEGM) signal and deriving a measure of electrical dyssynchrony from the intracardiac electrogram (IEGM) signal and wherein therapy is adjusted to improve both the measure of electrical dyssynchrony and the measure of interventricular fractionation.

45. The method of claim 41 further including detecting a significant deterioration in the measure of interventricular fractionation.

46. The method of claim 45 further including activating a warning device in response to detection of a significant deterioration in the measure of interventricular fractionation.

47. The method of claim 41 wherein adjusting therapy provided by the device is performed in a closed loop based on repeatedly updated measures of interventricular fractionation.

48. The method of claim 41 wherein the device is equipped to selectively deliver pacing at any of a plurality of pacing sites and wherein the ventricular pacing sites are selected so as to improve the measure of interventricular fractionation.

49. The method of claim 41 wherein detecting an interventricular cardiogenic impedance signal (Z_C) includes:

acquiring an activity signal along with Z_C;

detecting dZ_C/dt and compiling trends in dZ_C/dt; and

evaluating whether the activity signal is within an acceptable range and, if so, determining whether dZ_C/dt indicates a deterioration of interventricular fractionation; and

wherein the step of adjusting therapy provided by the device is performed in response to an indication of deterioration of interventricular fractionation.

50. A system for controlling therapy provided by an implantable cardiac stimulation device, the system comprising:

a cardiogenic impedance (Z_C) detector operative to detect an interventricular cardiogenic impedance signal (Z_C) associated with individual heartbeats, the interventricular cardiogenic impedance signal having an interventricular waveform morphology, the interventricular waveform morphology of individual heartbeats having features corresponding to periods of time when chambers of the heart are not beating uniformly due to mechanical dyssynchrony;

a cardiac function evaluation system operative to derive a measure of interventricular fractionation from the interventricular waveform morphology, wherein interventricular fractionation quantifies the features of the interventricular waveform morphology of individual heartbeats corresponding to the periods of time when chambers of the heart are not beating uniformly due to mechanical dyssynchrony; and

a cardiogenic impedance-based therapy adjustment system operative to adjust therapy provided by the device based on the interventricular cardiogenic impedance signal (Z_C) to improve the measure of interventricular fractionation and reduce periods of time when chambers of the heart are not beating uniformly due to mechanical dyssynchrony;

wherein the features of the interventricular waveform morphology corresponding to periods of time when chambers of the heart are not beating uniformly due to mechanical dyssynchrony include higher spectral frequencies compared to spectral frequencies associated with periods of time when chambers of the heart are beating uniformly and wherein the therapy adjustment system operates to adjust therapy to reduce at least some of the higher spectral frequencies to reduce interventricular fractionation.